IPC Indice de Precios Y Cotizaciones Ends 0.33% Lower at 55797.25 — Data Talk
The IPC Indice de Precios Y Cotizaciones is down 186.75 points or 0.33% today to 55797.25
--Down for three consecutive trading days
--Down 1033.07 points or 1.82% over the last three trading days
--Largest three-day point and percentage decline since Thursday, April 11, 2024
--Down six of the past seven trading days
--Off 4.96% from its record close of 58711.87 hit Wednesday, Feb. 7, 2024
--Lowest closing value since Tuesday, March 19, 2024
--Off 4.96% from its 52-week high of 58711.87 hit Wednesday, Feb. 7, 2024
--Up 15.77% from its 52-week low of 48197.88 hit Monday, Oct. 23, 2023
--Rose 2.60% from 52 weeks ago
--Off 4.96% from its 2024 closing high of 58711.87 hit Wednesday, Feb 7, 2024
--Up 1.99% from its 2024 closing low of 54707.89 hit Thursday, Jan. 18, 2024
--Month-to-date it is down 2.74%
--Year-to-date it is down 1589.00 points or 2.77%
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 16, 2024 17:14 ET (21:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track